1. Home
  2. CRGX vs ETWO Comparison

CRGX vs ETWO Comparison

Compare CRGX & ETWO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRGX
  • ETWO
  • Stock Information
  • Founded
  • CRGX 2021
  • ETWO 2000
  • Country
  • CRGX United States
  • ETWO United States
  • Employees
  • CRGX N/A
  • ETWO N/A
  • Industry
  • CRGX
  • ETWO EDP Services
  • Sector
  • CRGX
  • ETWO Technology
  • Exchange
  • CRGX Nasdaq
  • ETWO Nasdaq
  • Market Cap
  • CRGX 964.5M
  • ETWO 936.3M
  • IPO Year
  • CRGX 2023
  • ETWO N/A
  • Fundamental
  • Price
  • CRGX $12.81
  • ETWO $2.76
  • Analyst Decision
  • CRGX Strong Buy
  • ETWO Sell
  • Analyst Count
  • CRGX 6
  • ETWO 3
  • Target Price
  • CRGX $31.80
  • ETWO $3.70
  • AVG Volume (30 Days)
  • CRGX 229.0K
  • ETWO 1.0M
  • Earning Date
  • CRGX 11-12-2024
  • ETWO 01-07-2025
  • Dividend Yield
  • CRGX N/A
  • ETWO N/A
  • EPS Growth
  • CRGX N/A
  • ETWO N/A
  • EPS
  • CRGX N/A
  • ETWO N/A
  • Revenue
  • CRGX N/A
  • ETWO $619,301,000.00
  • Revenue This Year
  • CRGX N/A
  • ETWO N/A
  • Revenue Next Year
  • CRGX N/A
  • ETWO $3.01
  • P/E Ratio
  • CRGX N/A
  • ETWO N/A
  • Revenue Growth
  • CRGX N/A
  • ETWO N/A
  • 52 Week Low
  • CRGX $12.58
  • ETWO $2.76
  • 52 Week High
  • CRGX $33.92
  • ETWO $5.08
  • Technical
  • Relative Strength Index (RSI)
  • CRGX 30.99
  • ETWO 31.99
  • Support Level
  • CRGX $13.33
  • ETWO $2.89
  • Resistance Level
  • CRGX $15.26
  • ETWO $3.12
  • Average True Range (ATR)
  • CRGX 1.36
  • ETWO 0.13
  • MACD
  • CRGX -0.30
  • ETWO -0.01
  • Stochastic Oscillator
  • CRGX 3.51
  • ETWO 0.00

About CRGX CARGO Therapeutics Inc.

Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platform technologies, and manufacturing plan are designed to directly address the key limitations of approved cell therapies, including limited durability of effect, suboptimal safety and unreliable supply. The company's program, CRG-022, is a novel CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in a vast majority of B-cell malignancies.

About ETWO E2open Parent Holdings Inc.Class A

E2open Parent Holdings Inc is an end-to-end and cloud-based supply chain management SaaS platform. The company's software combines networks, data, and applications to provide a deeply embedded, mission-critical platform that allows customers to optimize the supply chain across channel shaping, business planning, logistics, trade, manufacturing, and supply management. The Group has one reportable segment consisting of cloud-based, end-to-end SCM software. Geographically, the company operates in the Americas, Europe, and Asia Pacific, out of which the majority is from the Americas.

Share on Social Networks: